Page last updated: 2024-08-25

sofosbuvir and Infection

sofosbuvir has been researched along with Infection in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bourliere, M	1
Abd Elfatah, AS; Abdalla, NH; Abdel-Raheim, S; Abdulghany, HM; Khairy, RM; Zenhom, NM	1

Other Studies

2 other study(ies) available for sofosbuvir and Infection

Article	Year
Retreatment Options for Patients Who Failed Direct-Acting Antiviral Regimens Containing NS5A Inhibitors: Is Glecaprevir/Pibrentasvir a Valid and Robust Option? Gastroenterology, 2019, Volume: 157, Issue:6 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Humans; Infections; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Treatment Failure	2019
Association of IL-1β, IL-1RN, and ESR1 genes polymorphism with risk of infection and response to sofosbuvir plus daclatasvir combination therapy in hepatitis C virus genotype-4 patients. IUBMB life, 2018, Volume: 70, Issue:11 Topics: Antiviral Agents; Carbamates; Case-Control Studies; Drug Therapy, Combination; Egypt; Estrogen Receptor alpha; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Infections; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Liver Cirrhosis; Polymorphism, Genetic; Pyrrolidines; Sofosbuvir; Valine	2018

Article

Year

Retreatment Options for Patients Who Failed Direct-Acting Antiviral Regimens Containing NS5A Inhibitors: Is Glecaprevir/Pibrentasvir a Valid and Robust Option?

Gastroenterology, 2019, Volume: 157, Issue:6

Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Humans; Infections; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Treatment Failure

2019

Association of IL-1β, IL-1RN, and ESR1 genes polymorphism with risk of infection and response to sofosbuvir plus daclatasvir combination therapy in hepatitis C virus genotype-4 patients.

IUBMB life, 2018, Volume: 70, Issue:11

Topics: Antiviral Agents; Carbamates; Case-Control Studies; Drug Therapy, Combination; Egypt; Estrogen Receptor alpha; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Infections; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Liver Cirrhosis; Polymorphism, Genetic; Pyrrolidines; Sofosbuvir; Valine

2018